Medicinal plants may shield kidneys from antibiotic damage, review suggests

Aminoglycosides are among the most potent antibiotics available—drugs that can save lives when bacterial infections have grown resistant to everything else. Amikacin, the broadest-spectrum member of this class, is particularly valuable in hospital settings, where it treats serious infections of the lungs, bloodstream, and urinary tract. The drug works by binding to a bacterial ribosome and shutting down protein synthesis, a mechanism so effective that resistance to it remains rare. But there is a cost that clinicians have long known about and struggled to prevent: these antibiotics accumulate in the kidney's filtering tubules and trigger a cascade of cellular damage that can lead to nephrotoxicity—a decline in kidney function that, in severe cases, becomes acute kidney injury.

Once an aminoglycoside enters the bloodstream, kidney cells actively pull it in through a receptor called megalin. The drug then accumulates inside the tubular cells that line the proximal tubule, the section of the nephron responsible for filtering waste and reclaiming essential molecules. This buildup sets off a chain of damaging events that ultimately kills the cells. The result is measurable and serious: waste products begin to accumulate in the blood because the kidneys can no longer clear them efficiently. Among elderly patients—who are more likely to need powerful antibiotics and whose kidneys are already less resilient—drug-induced kidney damage occurs in as many as 66% of cases. Across all age groups, medications account for roughly one in five cases of nephrotoxicity. For a subset of patients who have no other treatment options, this side effect represents a genuine dilemma: the antibiotic may be necessary to survive the infection, but it may also damage the organ system that keeps them alive.

Clinicians detect this damage through blood and urine tests that measure four markers: blood urea nitrogen, serum creatinine concentration, glomerular filtration rate, and creatinine clearance. A rise in serum creatinine of 50% or more signals that tubular damage is already underway. A new review article, published in the Journal of Current Indian Science by researchers including Astha Chaudhary, Monika Singh, Moumita Barman, and S. Sadish Kumar, examines whether medicinal plants might offer a way to interrupt this damage before it takes hold.

The authors surveyed eleven plants with documented nephroprotective properties: Aegle marmelos, Bauhinia purpurea, Cassia auriculata, Glycyrrhiza glabra, Orthosiphon stamineus, Pistacia atlantica, Vernonia cinerea, Costus afer, Euphorbia paralias, Descurainia sophia, and Trema guineensis. Each contains bioactive compounds that work through three broad mechanisms. Some reduce the inflammatory response that aminoglycosides trigger in kidney tissue. Others neutralize reactive oxygen species—the unstable molecules that the drug generates inside cells and that drive much of the cellular damage. Still others stabilize cell membranes and help tubular epithelial cells survive chemical stress. Together, these properties allow plant-derived compounds to interrupt the damage cascade at multiple points simultaneously—an advantage that single-mechanism synthetic drugs do not offer.

The practical appeal is clear. Because these plant compounds act through biological pathways entirely separate from the antibiotic's mechanism of action, there is no inherent reason why herbal extracts could not be given alongside aminoglycosides without compromising the drug's ability to kill bacteria. Herbal remedies are also generally free of the adverse effects that synthetic nephroprotective agents often carry, making them particularly attractive for patients already taking multiple medications. Yet the review itself is grounded in existing preclinical and pharmacological literature rather than in new experimental data. The authors acknowledge that moving from documented bioactive properties to validated clinical protection requires further structured investigation: standardized extraction protocols, dose-response studies, and ultimately controlled trials in patients actually receiving aminoglycoside therapy. Until that work is done, the promise remains theoretical—a direction worth pursuing, but not yet a clinical reality.